OTC: HYEX
HEALTHY EXTRACTS INC.CIK 0001630176 · SIC 2833 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (FLO 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade HYEX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q2 ended Jun 30, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 2,067,212 | 968,656 |
| Cost of revenue / cost of sales | 614,768 | 375,828 |
| Gross profit | 1,452,444 | 592,827 |
| Operating expenses: | ||
| General and administrative | 1,501,206 | 698,434 |
| Total operating expenses | 1,501,206 | 698,434 |
| Other income/(expense), net | (80,626) | 172,727 |
| Net income | (129,389) | 67,120 |
Consolidated Balance Sheets (Unaudited)
| Description | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 189,958 | 146,935 |
| Accounts receivable, net | 607,018 | 187,750 |
| Inventories | 644,114 | 843,357 |
| Other current assets | 89,102 | — |
| Total current assets | 1,679,466 | 1,327,317 |
| Operating lease right-of-use assets, net | — | |
| Finite-lived intangible assets, net | 3,884,990 | 4,233,083 |
| Goodwill | 26,056,515 | 21,123,922 |
| Other long-term assets | 987,878 | 1,140,342 |
| TOTAL ASSETS | 32,608,849 | 27,824,664 |
| Current liabilities: | ||
| Notes payable, current | 927,824 | — |
| Convertible notes, current | — | 111,330 |
| Accounts payable | 340,515 | 108,496 |
| Current portion of operating lease liabilities | 196,815 | 171,930 |
| Accrued liabilities | 592,602 | 613,645 |
| Other current liabilities | 6,331,329 | 757,768 |
| Total current liabilities | 8,389,085 | 1,763,169 |
| Operating lease liabilities | 229,110 | 344,265 |
| Other long-term liabilities | 1,554,963 | 1,687,665 |
| Total liabilities | 10,173,158 | 3,795,099 |
| Shareholders' equity: | ||
| Common stock | 368,443 | 368,413 |
| Capital in excess of stated value | 46,410,732 | 43,788,013 |
| Retained earnings (deficit) | (20,450,948) | (20,121,462) |
| Treasury stock | (3,892,536) | (5,400) |
| Total shareholders' equity | 22,435,692 | 24,029,564 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 32,608,849 | 27,824,664 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended Jun 30, 2026 | Six months ended Jun 30, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | 411,983 | 77,236 |
| Investing Activities: | ||
| Net cash from investing activities | 95,971 | (19,302) |
| Financing Activities: | ||
| Net cash from financing activities | (464,931) | 30,540 |
| Net increase/(decrease) in cash | 43,023 | 88,474 |
Amounts in USD as reported; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗